New shot aims to tame ulcerative colitis Flare-Ups
NCT ID NCT07463183
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether MK-8690, a drug given as a shot, can help people with moderate-to-severe ulcerative colitis achieve remission. About 100 adults who haven't responded well to other treatments will receive either MK-8690 or a placebo. The main goal is to see if more people on the drug reach clinical remission after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-8690 (also called PRA052), a drug given as a shot under the skin
What this could lead to
If it works, this could point toward a new treatment option for people with moderate-to-severe ulcerative colitis who haven't responded to other therapies.
What could go wrong
This is an early Phase 2a trial with only 100 participants, so results may not apply to everyone. The drug could cause side effects or fail to show benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BVL Research - Kansas ( Site 1054)
RECRUITINGLiberty, Missouri, 64068, United States
Contact Phone: •••-•••-••••
-
Clinnova Research ( Site 1042)
RECRUITINGAnaheim, California, 92805, United States
Contact Phone: •••-•••-••••
-
Gastroenterology Associates of Central Georgia ( Site 1060)
RECRUITINGMacon, Georgia, 31201, United States
Contact Phone: •••-•••-••••
-
Nature Coast Clinical Research ( Site 1045)
RECRUITINGInverness, Florida, 34452, United States
Contact Phone: •••-•••-••••
-
Peak Gastroenterology Associates ( Site 1052)
RECRUITINGColorado Springs, Colorado, 80907, United States
Contact Phone: •••-•••-••••
-
Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072)
RECRUITINGMiami, Florida, 33134, United States
Contact Phone: •••-•••-••••
-
South Denver Gastroenterology, PC ( Site 1068)
RECRUITINGEnglewood, Colorado, 80113, United States
Contact Phone: •••-•••-••••
-
Tulane University School of Medicine ( Site 1073)
RECRUITINGNew Orleans, Louisiana, 70112, United States
Contact Phone: •••-•••-••••
-
University of Kansas Medical Center ( Site 1077)
RECRUITINGKansas City, Kansas, 66160, United States
Contact Phone: •••-•••-••••